PortalPublikationenEffect of bortezomib and cetuximab in EGF-stimulated HNSCC.

Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.

Standard

Effect of bortezomib and cetuximab in EGF-stimulated HNSCC. / Wagenblast, Jens; Baghi, Mehran; Arnoldner, Christoph; Bisdas, Sotirios; Gstöttner, Wolfgang; Ackermann, Hanns; May, Angelika; Knecht, Rainald; Hambek, Markus.

in: ANTICANCER RES, Jahrgang 28, Nr. 4, 4, 2008, S. 2239-2243.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wagenblast, J, Baghi, M, Arnoldner, C, Bisdas, S, Gstöttner, W, Ackermann, H, May, A, Knecht, R & Hambek, M 2008, 'Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.', ANTICANCER RES, Jg. 28, Nr. 4, 4, S. 2239-2243. <http://www.ncbi.nlm.nih.gov/pubmed/18751401?dopt=Citation>

APA

Wagenblast, J., Baghi, M., Arnoldner, C., Bisdas, S., Gstöttner, W., Ackermann, H., May, A., Knecht, R., & Hambek, M. (2008). Effect of bortezomib and cetuximab in EGF-stimulated HNSCC. ANTICANCER RES, 28(4), 2239-2243. [4]. http://www.ncbi.nlm.nih.gov/pubmed/18751401?dopt=Citation

Vancouver

Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H et al. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC. ANTICANCER RES. 2008;28(4):2239-2243. 4.

Bibtex

@article{66e93c26a2384339935b7501d295fddd,
title = "Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.",
abstract = "BACKGROUND: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, the antitumor effect of bortezomib (Velcade) in combination with cetuximab was investigated in epidermal growth factor (EGF)-stimulated head and neck squamous cell carcinoma cell lines (HNSCC). MATERIALS AND METHODS: Dose escalation studies were performed with five EGF-stimulated squamous cell carcinoma cell lines using bortezomib alone or in combination with cetuximab. Growth inhibitory and cell decline effects were measured quantitatively using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) and lactate dehydrogenase (LDH) assay. RESULTS: Bortezomib alone showed no significant antiproliferative activity in any EGF-stimulated HNSCC cell line (p > 0.05), whereas the combination of bortezomib and cetuximab had highly significant antitumoral activity (p <0.043). CONCLUSION: Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in EGF-stimulated HNSCC cell lines. A combination treatment of HNSCC with bortezomib and cetuximab may allow a therapeutical regimen to be developed that is less toxic than the conventional drugs used for these tumors.",
author = "Jens Wagenblast and Mehran Baghi and Christoph Arnoldner and Sotirios Bisdas and Wolfgang Gst{\"o}ttner and Hanns Ackermann and Angelika May and Rainald Knecht and Markus Hambek",
year = "2008",
language = "Deutsch",
volume = "28",
pages = "2239--2243",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

RIS

TY - JOUR

T1 - Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.

AU - Wagenblast, Jens

AU - Baghi, Mehran

AU - Arnoldner, Christoph

AU - Bisdas, Sotirios

AU - Gstöttner, Wolfgang

AU - Ackermann, Hanns

AU - May, Angelika

AU - Knecht, Rainald

AU - Hambek, Markus

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, the antitumor effect of bortezomib (Velcade) in combination with cetuximab was investigated in epidermal growth factor (EGF)-stimulated head and neck squamous cell carcinoma cell lines (HNSCC). MATERIALS AND METHODS: Dose escalation studies were performed with five EGF-stimulated squamous cell carcinoma cell lines using bortezomib alone or in combination with cetuximab. Growth inhibitory and cell decline effects were measured quantitatively using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) and lactate dehydrogenase (LDH) assay. RESULTS: Bortezomib alone showed no significant antiproliferative activity in any EGF-stimulated HNSCC cell line (p > 0.05), whereas the combination of bortezomib and cetuximab had highly significant antitumoral activity (p <0.043). CONCLUSION: Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in EGF-stimulated HNSCC cell lines. A combination treatment of HNSCC with bortezomib and cetuximab may allow a therapeutical regimen to be developed that is less toxic than the conventional drugs used for these tumors.

AB - BACKGROUND: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, the antitumor effect of bortezomib (Velcade) in combination with cetuximab was investigated in epidermal growth factor (EGF)-stimulated head and neck squamous cell carcinoma cell lines (HNSCC). MATERIALS AND METHODS: Dose escalation studies were performed with five EGF-stimulated squamous cell carcinoma cell lines using bortezomib alone or in combination with cetuximab. Growth inhibitory and cell decline effects were measured quantitatively using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) and lactate dehydrogenase (LDH) assay. RESULTS: Bortezomib alone showed no significant antiproliferative activity in any EGF-stimulated HNSCC cell line (p > 0.05), whereas the combination of bortezomib and cetuximab had highly significant antitumoral activity (p <0.043). CONCLUSION: Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in EGF-stimulated HNSCC cell lines. A combination treatment of HNSCC with bortezomib and cetuximab may allow a therapeutical regimen to be developed that is less toxic than the conventional drugs used for these tumors.

M3 - SCORING: Zeitschriftenaufsatz

VL - 28

SP - 2239

EP - 2243

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 4

M1 - 4

ER -